Rocket Pharmaceuticals Highlights Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

  • Jonathan Schwartz,

Press/Media

Period22 Jul 2020

Media coverage

1

Media coverage

  • TitleRocket Pharmaceuticals Highlights Phase 1 Trial of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency
    Media name/outletManufacturing Close-Up
    Country/TerritoryUnited States
    Date22/07/20
    PersonsJonathan Schwartz,
View all 1
View less